View Author
c 1-inh patient attack study 1-inh treatment 1-inhibitor inhibitor c 1-inhibitor angioedema pneumonia activity level protein c prophylactic protein pneumoniae range effect plasminogen antithrombin tissue c 1 inhibitor coagulation activator number factor anticoagulant c 4 levels product blood pathway netherland heparin pharmacokinetic prophylactic study sepsis saline flammatory cetor injury prophylactic treatment parameter 48 hrs pneumoniae pneumonia c 4 level medication safety bronchoalveolar tissue plasminogen activator assay angioedema attacks on-demand study flammatory response prophylaxi process hae patients efficacy result manufacturing process on-demand allergy response administration c 1-inhibitor levels concentration plasminogen activator activity c 1inh aae patient plasminogen activator inhibitor c 1-inhibitor antigen therapy streptococcus pneumoniae pneumonia allergy asthma immunol activation flammation immunol murine pneumococcal pneumonia lavage period
2 Most Recent Publications
|
Treatment of hereditary angioedema with nanofiltered C1-esterase inhibitor concentrate (Cetor®): Multi-center phase II and III studies to assess pharmacokinetics, clinical efficacy and safety
(Article)
Hofstra, J.J.H. Budde, I.K. Strengers, P.F.W. Twuyver, E. van Choi, G. Levi, M. Leebeek, F.W.G. Monchy, J.G. de Ypma, P.F. Keizer, R.J.W. de Huitema, A.D.R. |
2012-03-01
|
|
Antithrombin inhibits bronchoalveolar activation of coagulation and limits lung injury during Streptococcus pneumoniae pneumonia in rats
(Article)
Choi, G. Hofstra, J.J.H. Roelofs, J.J.T.H. Rijneveld, A.W. Bresser, P. Zee, J.S. van der Florquin, S. Poll, T. van der Levi, M. Schultz, M.J. |
2008-01-01
|
